Companies › GeneCradle
3 active drug programs in 7 registered trials: 6 Phase 1, 1 Phase 3; Metabolic and endocrine, Neurology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GC101 Self-complementary AAV9 delivering codon-optimized SMN coding sequence | SMN1 | Phase 3 | SMA - Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy; SMA II | Dec 2026 |
| GC301 AAV9 vector delivering functional human GAA gene | GAA | Phase 1 | Pompe Disease Infantile-Onset; Pompe Disease (Late-onset) | Dec 2026 |
| GC304 self-complementary AAV5 carrying codon-optimized LPL gene driven by liver-specific promote | LPL | Phase 1 | Hypertriglyceridemia, Familial | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06421831 | GC101 | Phase 1 | Spinal Muscular Atrophy Type 3 | Neurology | Dec 2026 |
| NCT05824169 | GC101 | Phase 1 | Spinal Muscular Atrophy | Neurology | Dec 2026 |
| NCT05793307 | GC301 | Phase 1 | Pompe Disease Infantile-Onset | Metabolic and endocrine | Dec 2026 |
| NCT06391736 | GC301 | Phase 1 | Pompe Disease (Late-onset) | Metabolic and endocrine | Dec 2026 |
| NCT05860569 | GC304 | Phase 1 | Hypertriglyceridemia, Familial | Metabolic and endocrine | Dec 2026 |
| NCT06971094 | GC101 | Phase 3 | SMA - Spinal Muscular Atrophy | Other | Dec 2026 |
| NCT05901987 | GC101 | Phase 1 | SMA II | Neurology | Dec 2028 |
Novartis Gemma Biotherapeutics Lanyue Biotech (Hangzhou) Biocad Lantu Biopharma Astellas Amicus Therapeutics Sanofi Spark Therapeutics AskBio
Spark Therapeutics Neurogene Orchard Therapeutics AskBio Shanghai Vitalgen BioPharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.